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Abstract
PURPOSE: To evaluate the Aegis software implementation for real-time calculation of functional tumor volume
(FTV) in the neoadjuvant breast cancer treatment trial setting. METHODS: The validation data set consisted of
689 contrast-enhanced magnetic resonance imaging (MRI) examinations from the multicenter American Col-
lege of Radiology Imaging Network 6657 study. Subjects had stage III tumors ≥3 cm in diameter and under-
went MRI before, during, and after receiving anthracycline-cyclophosphamide chemotherapy. Studies were
previously analyzed by the University of California San Francisco core laboratory using the three-timepoint sig-
nal enhancement ratio (SER) FTV algorithm; FTV measurement was subsequently implemented on the Hologic
(formerly Sentinelle Medical Inc) Aegis platform. All cases were processed using predefined volumes of inter-
est with no user interaction. Spearman rank correlation was evaluated for all study sites and visits. Cox pro-
portional hazards analysis was used to compare predictive performance of the platforms for recurrence-free
survival (RFS) time. RESULTS: Overall agreement between platforms was good; ρ varied from 0.96 to 0.98 for
different study visits. Site-by-site analysis showed considerable variation, from ρ = 0.54 to near perfect
agreement (ρ = 1.000) for several sites. Mean absolute difference between platforms ranged from 1.67 cm3
pretreatment to 0.2 cm3 posttreatment. The two platforms showed essentially identical performance for pre-
dicting RFS using pretreatment or posttreatment FTV. CONCLUSION: Implementation of the SER FTV algorithm
on a commercial platform for real-time MRI volume assessments showed very good agreement with the refer-
ence core laboratory system, but variations by site and outlier analysis point out sensitivities to implementation-
specific differences.
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Introduction
Dynamic contrast-enhanced magnetic resonance imaging (DCE-
MRI) is widely used to evaluate tumors in patients with locally
advanced breast cancer who are undergoing neoadjuvant (preopera-
tive) chemotherapy. Signal enhancement in T 1-weighted DCE-
MRI is typically assessed by using a semiquantitative method to
estimate signal intensity changes or by using a pharmacokinetic
model to quantify changes in tissue contrast agent concentration [1].
Pharmacokinetic models provide parameters that describe changes
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in perfusion and blood vessel permeability [2–5], but implementing
them requires sacrificing imaging spatial resolution for high temporal
resolution [6].
Because of the importance of tumor morphology for diagnosis in
breast MRI, images with high spatial resolution and high signal-to-
noise ratio are preferable to images with high temporal resolution but
low spatial resolution and low signal-to-noise ratio. Previous studies have
demonstrated the value of high spatial resolution three-dimensional
(3D)DCE-MRI with relatively low temporal resolution (60-90 seconds
per frame) [7,8] for assessing breast tumors. Moreover, methods based
on sampling three time points (one precontrast and two postcontrast)
with high spatial resolution 3D imaging and approximate isotropic
pixel sizes of 1 × 1 × 1 mm covering the entire symptomatic breast are
commonly used in clinical studies [8–10] to assess morphologic changes
in breast lesions.
We previously published a three-timepoint acquisition strategy to
calculate high spatial resolution maps of a semiquantitative param-
eter, the signal enhancement ratio (SER), for clinical studies of breast
cancer [11]. SER is defined as (S1 − S0)/(S2 − S0), where S0, S1, and
S2 represent the signal intensity of each voxel in the precontrast, first
postcontrast (tp1), and second postcontrast (tp2) images, respectively.
SER analysis gives rise to several metrics including the functional
tumor volume (FTV), defined as the sum volume of all voxels meet-
ing a minimum early percentage of enhancement [PE = 100 × (S1 −
S0)/S0] threshold with SER in a designated range. The utility of such
metrics has led to the use of SER volumetric analysis in multicenter
clinical trials, including the American College of Radiology Imaging
Network (ACRIN) 6657 trial (the largest multicenter trial completed
to date using MRI to measure treatment response in primary breast
cancers) and the imaging component of the Investigation of Serial
studies to Predict Your Therapeutic Response with Imaging And
moLecular analysis (I-SPY TRIAL). In ACRIN 6657, FTVs derived
from SER analysis were shown to better predict pathologic complete
response than clinical assessment [12].
To ensure consistency in methodology, SER volumetric analysis for
all sites participating in ACRIN 6657 was performed at the Breast
Imaging Research Program at theUniversity of California San Francisco
(UCSF; San Francisco, CA), which served as an imaging core labo-
ratory for the trial. Although such an arrangement is feasible for
smaller trials, it is unsustainable in larger trials or for widespread clinical
use. Hence, in preparation for the I-SPY 2 TRIAL (an adaptively ran-
domized phase II trial designed to identify novel agents for breast
cancer), and under the framework of a National Institute of Health
grant specifically geared toward promoting translation of in vivo imag-
ing systems for cancer investigations (PAR-10-169; R01 CA132870),
an academic-industrial partnership was established between the UCSF
core laboratory and Sentinelle Medical Inc. The goal of the academic-
industrial partnership grant was to implement theUCSF SER algorithm
as a software module on the Sentinelle Aegis platform and to sub-
sequently distribute Aegis systems to sites participating in the I-SPY 2
study for FTV measurement.
The purpose of the study presented here was two fold: 1) to eval-
uate the level of agreement between FTV measurements using UCSF
core laboratory software and Aegis software, by site and by treatment
time point, and 2) to investigate whether FTV derived from SER
analysis using the Aegis platform performs comparably to the UCSF
software for predicting 3-year recurrence-free survival (RFS). To accom-
plish these objectives, the Aegis platform was used to perform SER anal-
ysis of the ACRIN 6657 trial data set.
Materials and Methods
Data Acquisition
A detailed description of protocols in the ACRIN 6657 trial have
been reported elsewhere [12]. A summary is presented here.
Subject recruitment. The ACRIN 6657 trial was conducted as the
imaging arm of the larger I-SPY TRIAL, which also included a bio-
marker study, Cancer and Leukemia Group B (CALGB) 150007.
Patients enrolling in CALGB 150007 with stage III tumors that
measured at least 3 cm in diameter at clinical examination or imaging
and who were receiving an anthracycline-cyclophosphamide regimen
alone or followed by a taxane were eligible. Pregnant patients and
those with ferromagnetic prostheses were excluded from the study.
All participants were consented according to a process approved by the
American College of Radiology Institutional Review Board and local-
site institutional review boards. A total of 207 of 238 female subjects
with analyzable DCE-MRI examinations and mean age at enrollment
47.9 years (range = 26–68 years) were included in this validation study.
Imaging procedures. MRI examinations were performed within
4 weeks before the start of anthracycline-cyclophosphamide chemo-
therapy (visit 1), at least 2 weeks after the first cycle and before the
second cycle of anthracycline-cyclophosphamide chemotherapy (visit 2),
between anthracycline-cyclophosphamide treatment and taxane therapy
if taxane was administered (visit 3), and after the final chemotherapy
treatment and before surgery (visit 4). MRI examinations were begun
in June, 2002 and concluded in August, 2006, with studies submitted
from nine imaging centers all located within the United States.
All MRI was performed on 1.5-Tesla scanners from GE Healthcare
(Pewaukee, WI), Siemens Healthcare (Erlangen, Germany), and
Philips Healthcare (Best, The Netherlands) using dedicated breast
radiofrequency coils. Before the start of imaging, an IV catheter was
inserted into each patient; patients were imaged in the prone position.
TheMRI protocol included a localization acquisition and aT 2-weighted
sequence, followed by a dynamic contrast-enhanced series. For the
contrast-enhanced series, high spatial-resolution (in-plane spatial reso-
lution, ≤1 mm) 3D fat-suppressed T 1-weighted imaging of the
symptomatic breast was performed using a gradient-echo sequence with
a repetition time of 20 milliseconds or less, echo time of 4 to 5 milli-
seconds, flip angle of 45° or less, 16- to 18-cm field of view, minimum
matrix of 256 × 192, and 64 sections with a thickness of 2.5 mm or less.
Imaging time for the T 1-weighted sequence was required to be
between 4.5 and 5 minutes per volume data set (phase), with one phase
acquired before contrast injection and at least two phases acquired
commencing immediately after injection. Pulse sequences for these
acquisitions were required to have k-space ordering set to sample the
most significant center of k-space region at the midpoint of the acqui-
sition period, resulting in a temporal sampling point for the first
contrast-enhanced phase between 2minutes, 15 seconds and 2minutes,
30 seconds. An interphase delay between the first and the second
contrast-enhanced phase was allowed as needed to result in a temporal
sampling point of the second contrast-enhanced phase between 7 min-
utes, 15 seconds and 7 minutes, 45 seconds.
Data Analysis
Volumetric analysis. Staff at the imaging core laboratory per-
formed the quantitative analysis of all MR image data. Rectangular
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3D volumes of interest (VOI) were defined manually on all DCE
series to completely enclose the enhancing tumor, and early PE =
[(S1 − S0)/S0] × 100% and SER = (S1 − S0)/(S2 − S0) were computed
for all voxels, where S0, S1, and S2 represent the signal intensities
on the precontrast, early postcontrast, and late postcontrast images,
respectively. For this validation study, the lowest order volume FTV
(SER > 0) was computed as the sum of voxels with positive SER
meeting a specified threshold for early PE. Two additional filters—
a minimum precontrast intensity filter and a requirement for a min-
imum number of connected high-PE voxels—were applied to elim-
inate background and fat regions and isolated high-PE voxels
resulting from noise. The connected voxels filter was imposed in
three dimensions, testing for a specified minimum number of
high-PE voxels among the 26 nearest neighbor voxels surrounding
each voxel. Nominal values of 70% for the early PE threshold,
60% of the VOI intensity maximum for the precontrast minimum-
intensity level, and four neighboring high-PE voxels for the minimum
connectivity kernel were chosen on the basis of earlier single-site data
from UCSF. However, adjustments to these values were necessary to
account for variability in MRI systems and imaging parameters. These
adjustments were made on a site-specific basis, so all studies from a
given site were processed with identical parameter values. For cases
where significant nontumor enhancing regions (for example, large
vessels) could not be excluded through careful selection of the rec-
tangular VOI, one or more irregular “omit” regions were defined
by the user to exclude these volumes from the analysis. Nonanalyzable
cases included those in which SER analysis could not be performed
due to an insufficient number of postcontrast phases, image mis-
registration, poor image quality, or major protocol violations. We
expect that these rejection criteria are independent of a subject’s SER
FTV value, i.e., the reason that data are missing is not correlated
with the unobserved data. The data in this case are considered “missing
at random” [13], and therefore, there is no need for any explicit cor-
rection of the analysis due to the existence of missing data.
Analysis platforms. All cases were initially analyzed with a software
package developed at UCSF for analysis of breast DCE-MRI studies,
with final results submitted to ACRIN in 2008 after the close of the
6657 study. Beginning in 2007, UCSF teamed with Sentinelle Medical
Inc (Toronto, Ontario; acquired by Hologic Inc, Bedford, MA, in
2010), manufacturer of the Aegis visualization system, to develop
and provide an SER FTV analysis platform for use at imaging sites
in the I-SPY 2 TRIAL. The algorithms developed at UCSF were
adapted and ported to the Aegis software platform. All capabilities of
the UCSF SER FTV analysis programs were replicated except for
the “omit” functionality for excluding irregular regions from the
VOI. In addition to real-time processing capability for analyzing on-
going studies, a batch-processing capability was implemented to process
large numbers of cases with predefined VOI without operator inter-
action. Parameters for the different filtering steps in the SER FTV
analysis (minimum early PE,minimumprecontrast intensity, andmini-
mum connected high-PE voxels) were set on a site-by-site basis to be
identical with those used in the UCSF analysis. All analyzable cases
from the ACRIN 6657 study were processed through the batch pro-
cessor for this validation study.
Statistics. The relationship between FTVs computed with the imag-
ing core laboratory’s implementation and FTVs computed with the
Aegis implementation was assessed using scatterplots and Spearman
rank correlation coefficient (ρ). The differences between the FTVs
from the two software platforms were evaluated using the mean differ-
ence (MD), given by the mean value of the magnitude of the difference
between the two results. FTVs from across all sites were compared at
each visit in a combined analysis (ignoring potential between-site var-
iability). To evaluate between site variability, FTVs were also compared
at each visit for each site separately. Two sites in the trial accrued a
single patient, and another site had fewer than four patients at three
of the four visits; data from these sites and visits were only included
in the comparison of FTVs across sites because these data sets were
too small to obtain meaningful correlation estimates.
Single-predictor Cox proportional hazards modeling was used to
examine the relationship between FTV measurements and RFS.
RFS was defined as the time (number of days) between first chemo-
therapy treatment and disease recurrence according to the standard-
ized definitions for efficacy end points (STEEP) criteria [13]. The
Cox model explicitly accounts for differential follow-up, so no cut
points for defining recurrence were required for this analysis. FTVs
Table 1. Total and Analyzable Examinations from Each Study Site.
Site 1 2 3 4 5 6 7 8 9 All
n (total) 135 13 116 67 22 182 49 7 255 846
n (analyzable) 108 1 76 42 11 155 48 1 248 690
Table 2. Correlation of Software Platform Results by Visit for All Sites.
Site Parameter Visit 1 Visit 2 Visit 3 Visit 4
All sites n 175 175 166 174
ρ 0.962 0.958 0.981 0.972
95% CI (0.949‐0.971) (0.944‐0.969) (0.974‐0.986) (0.962‐0.979)
MD (cm3) 1.67 1.21 0.27 0.20
Excluding site 3 n 156 156 149 152
ρ 0.999 0.977 0.980 0.990
95% CI (0.998‐0.999) (0.968‐0.983) (0.972‐0.985) (0.986‐0.992)
MD (cm3) 1.24 0.88 0.26 0.11
Site 1 n 27 28 26 27
ρ 0.998 0.995 1.000 1.000
95% CI (0.995‐0.999) (0.996‐0.999) (0.998‐1.000) (0.988‐0.998)
MD (cm3) 0.59 0.52 0.34 0.05
Site 3 n 19 19 17 21
ρ 0.54 0.74 0.95 0.858
95% CI (0.113‐0.798) (0.43‐0.894) (0.863‐0.982) (0.677‐0.941)
MD (cm3) 5.22 3.96 0.4 0.79
Site 4 n 10 12 10 10
ρ 1.000 0.979 0.964 1.000
95% CI (1.000‐1.000) (0.925‐0.994) (0.849‐0.992) (1.000‐1.000)
MD (cm3) 0.48 0.73 1.38 0.04
Site 6 n 37 41 38 39
ρ 0.999 0.997 0.939 0.969
95% CI (0.998‐1.000) (0.995‐0.999) (0.884‐0.968) (0.941‐0.984)
MD (cm3) 2.22 1.73 0.22 0.34
Site 7 n 13 11 12 12
ρ 1.000 1.000 0.999 1.000
95% CI (1.000‐1.000) (1.000‐1.000) (1.000‐1.000) (0.995‐0.997)
MD (cm3) 1.39 0.27 0.16 0.04
Site 9 n 63 61 61 63
ρ 1.000 1.000 1.000 1.000
95% CI (1.000‐1.000) (0.999‐1.000) (0.988‐0.996) (0.985‐0.994)
MD (cm3) 0.35 0.08 0.06 0.03
P < .0001 in all cases except for site 3, visit 1 (P < .017) and site 3, visit 2 (P < .0003).
MD, mean difference, the mean value of the magnitude difference between the FTV calculated
with the core laboratory and Aegis software platforms.
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at visit 1 (FTV1) and visit 4 (FTV4) were considered. All Cox pro-
portional hazards results were reported as estimated hazard ratios
with Wald 95% confidence intervals (CIs) and likelihood ratio test
P values. All statistical analyses were performed using the R project
for statistical computing (http://www.r-project.org; Vienna, Austria)
and the survival library therein. A nominal statistical significance level
of α = 0.05 was used throughout.
Results
Nine imaging centers contributed a total of 846 on-study MRI exam-
inations. Of these, 689 examinations in 207 patients were acceptable
for tumor volume quantification. Reasons for excluding examinations
included patient ineligibility or withdrawal of consent, insufficient
MRI image quality, and significant protocol violations. The most
common image quality problems were insufficient or spatially varying
fat suppression, poor SNR, and image misregistration due to motion.
Protocol violations that prevented FTV analysis included failure to
acquire at least two postcontrast DCE phases, use of a two-dimensional
rather than 3D acquisition, and failure to keep all MRI acquisition
parameters constant between precontrast and postcontrast acquisitions.
The numerical distribution of exams submitted and accepted from the
different study sites is shown in Table 1.
Agreement between the software platforms was assessed indepen-
dently at each study visit, as mean tumor volume decreased signifi-
cantly with treatment. We observed high correlation between FTVs
generated by the two platforms at all visits, as shown by the Spearman
rank correlation analysis results summarized at the top of Table 2.
The correlation ranged from the weakest at visit 2 (n = 175, ρ =
0.958, 95% CI = 0.944-0.969) to the highest at visit 3 (n = 166, ρ =
0.981, 95% CI = 0.974-0.986), with P < .0001 at all visits. MD values
decreased steadily with successive visits: 1.67, 1.21, 0.27, and 0.20 cm3
for visits 1 to 4, respectively. The generally high agreement between
software platforms is shown graphically through Bland-Altman plots
for each visit in Figure 1, as well as the presence of some outliers at
all visits.
FTVs from the two software platforms broken down by both site
and visit were examined to investigate site-to-site differences and pos-
sible outlier effects. The three sites with very low numbers of analyzable
cases (Table 1; sites 2, 5, and 8) were excluded from this analysis.
Results for Spearman rank correlation and MD are shown in Table 2,
and representative scatterplots for the first and fourth visits are shown
in Figure 2 for the sites with the weakest (site 3) and highest (site 9)
correlations. Due to therapeutic effects, many patients have significant
volume reduction over the course of treatment, resulting in FTV values
at or near 0 cm3 by visit 4, as shown in the insets in Figure 2, B and D.
Estimates of correlation coefficients across sites and visits ranged from
a low of ρ = 0.54 (n = 19, 95% CI = 0.113-0.798; P < .017) for site
3 at visit 1 up to ρ = 1.000 (95% CI = 1.000-1.000; P < .0001) for
five different site + visit combinations. Estimates of the correlation
Figure 1. Bland-Altman plots of the difference between core laboratory FTV and Aegis platform FTV (FTVCore− FTVAegis) versus the mean
of the two measures for all sites for study visit 1 (A) through visit 4 (D). Inset legends give the results from the Spearman rank correlation
analysis for the shown studies.
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coefficient at the other four sites with sufficient analyzable data (sites 1,
4, 6, and 7) were greater than 0.93 (P < .0001) for all visits, as shown in
Table 2. Values of the MD are shown graphically for all sites and visits
in Figure 3. They ranged from a maximum of 5.22 cm3 (site 3, visit 1)
to 0.03 cm3 (site 9, visit 4). We repeated the correlation analysis for all
sites combined excluding all examinations from site 3, with resulting
increases in ρ and reduction in MD values as shown in Table 2. Exam-
ination of the plots in Figures 1 and 2 reveals that the errors are not
normally distributed, a majority of the points lying almost perfectly
on the identity line with only a small subset showing differences of a
significant magnitude. Possible explanations for the anomalously poor
correlations for site 3 and for the large differences in FTVs from some
individual MRI exams are given in Discussion section.
The capability of the core laboratory software platform to exclude
irregularly shaped “omit” regions of interest (ROIs) from the analysis
was not supported by the Aegis implementation. Omit regions were
defined in 107 of the 689 analyzed exams, resulting in an over-
estimation of FTV by the Aegis platform in these cases relative to
the core laboratory values. The excluded enhancing volumes were
generally small, and eliminating these 107 exams from the correlation
analysis for all sites combined resulted in no systematic changes in
the estimated correlation coefficients or MD results for each visit.
However, when the analysis was broken down by site, some changes
were observed in the deviation of the slope of the regression line from
an ideal value of 1. For site 6, the most extreme example, there was an
average 9% overestimation of FTV by Aegis software relative to the
Figure 2. Scatterplots of core laboratory FTV (vertical axis) versus Aegis platform FTV (horizontal axis) for site 3 [poorest correlations, visit 1
(A) and visit 4 (B)] and site 9 [best correlations, visit 1 (C) and visit 4 (D)]. The diagonal line represents the identity relationship. Expanded
scales are shown as insets to illustrate correlations at the small volume ranges typical for visit 4.
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core laboratory software, which was reduced to <1% when the cases
with omit regions were excluded. Omit regions were also responsible
for some significant outliers; for example, two visit four cases in which
Aegis software reported FTV values of 7.8 and 9.2 cm3 versus values of
4.1 and 0.9 cm3 as reported by the core laboratory software.
Survival analysis using the Cox proportional hazards model was
calculated for FTV values from each software platform for all sites
for the baseline (FTV1) and presurgery (FTV4) visits. Per unit increase
(1 cm3) in FTV1, the Aegis platform gave an estimated hazard ratio
of 1.010 (Wald 95% CI = 1.004-1.017; likelihood ratio P < .002).
The core laboratory platform gave a similar estimated hazard ratio of
1.011 (95% CI = 1.004-1.018; P < .001) for this visit. The estimated
hazard ratio and CI per unit increase in FTV4 was identical (to three
decimal places of hazard ratio) for both platforms: 1.043 (95% CI =
1.023-1.064; P < .0001).
Discussion
We compared FTV measured with an implementation of SER vol-
umetric analysis on Hologic’s Aegis platform to FTV measured by
the UCSF imaging core laboratory in the ACRIN 6657 trial. We
found very good overall concordance between the two platforms with
ρ ≥ 0.95 for all visits. However, analysis of individual sites showed
marked differences, and there were some outliers that bear explanation.
Site 3 exhibited poorer correlations than all the other sites. Exam-
ination of individual cases from this site indicated the following two
primary problems: cases with Digital Imaging and Communications
in Medicine (DICOM) file issues such as lack of scan timing infor-
mation, which interfered with the Aegis software’s ability to properly
calculate the FTV, resulting in 0 cm3 or significantly underestimated
volumes; and cases with poor image quality, typically due to poor fat
saturation. These problems point to the importance of good adherence
to both DICOM file transfer standards and study protocols, especially
for multicenter studies.
Several known implementation differences between the two soft-
ware platforms account for some of the differences observed in indi-
vidual cases. These differences, discussed in detail below, include
factors related to image orientation, PE value representation, ability
to omit regions within a VOI, VOI coordinate storage format, and
signal intensity thresholds used for analysis.
One limitation of the core laboratory platform implementation was a
requirement of sagittal image orientation; and although this orientation
was specified in the ACRIN 6657 study protocol, some examinations
were submitted with DCE images acquired in the axial orientation.
These images were processed as submitted by the Aegis software but
were interpolated to isotropic voxels and reformatted to the sagittal ori-
entation for processing by the core laboratory. However, of the 20 axial
exams submitted for six subjects, only 3 exams from a single subject
proved analyzable. This subject was from site 7, which had excellent
correlation (ρ≥ 0.999 at all visits), so these extra image-processing steps
did not appear to significantly affect the correlation results. However,
the exam from visit 1 for this subject was an outlier with a difference in
FTV of 5.6 cm3 between platforms, and excluding this subject reduced
the site 7, visit 1 MD from 1.39 to 1.04 cm3.
Another possible source of variation results from how the two plat-
forms maintain PE values; the core laboratory uses a 32-bit floating-
point number, whereas Aegis uses a 4-bit channel, binning the PE
into 10% levels from 10% to 160%. Because the PE thresholds used
for all sites were multiples of 10%, this is expected to have only small
effects on individual FTV measurements due to possible rounding
errors of voxels with PE values close to the selected threshold, but
it may have affected the correlation results.
A capability of the core laboratory platform that was not possible
to duplicate on the Aegis platform at the time of this study was an
ROI “omit” function, whereby the user could trace an irregularly
shaped ROI on a maximum-intensity projection image showing non-
tumor enhancing regions and have that region excluded from the vol-
ume calculation. This feature was used to exclude regions such as the
heart or large vessels that could not be excluded from the rectangular
VOI without also excluding tumor regions. Broken down by site, the
results indicate that this difference gave rise to an overall overestima-
tion of FTV relative to the core laboratory values, by up to 9% for
site 6, and significant errors on some individual cases. Following this
study, an “omit region” feature was added to a later version of the
Aegis platform SER FTV software for use in the I-SPY 2 study.
A final potential contributor of outliers involves the translation of
the manually defined VOI from the core laboratory system to the
Aegis platform. The VOI were stored on the core laboratory system
as pixel coordinates of the rectangular region but, for platform archi-
tecture reasons, needed to be translated to DICOM standard patient
coordinate system values for processing on the Aegis platform. These
patient coordinates were subsequently reconverted into pixel ranges
for the Aegis SER FTV analysis. This double conversion may have
introduced errors in replicating the exact VOI at the pixel level. The
direct effect of inclusion or exclusion of tumor regions on one plat-
form but not the other is expected to be minimal because the VOI
were defined to completely include enhancing regions with some
margin. However, a secondary effect arises because the histogram
of precontrast image intensity is used to calculate the minimum inten-
sity threshold, which has been observed to have significant impact on
the FTV, especially in cases of poor image quality or poor fat sup-
pression. We note that whatever the extent of this problem turns out
to be, it will be less of a factor in future studies such as I-SPY 2, as the
VOI will be defined directly on the Aegis system by the operator. We
are also investigating using different values for the intensity threshold
and different segmentation methods in an attempt to reduce the depen-
dence of the FTV analysis on the VOI definition.
The final check for validation was to measure the prediction of
RFS time using FTV from each platform. We found no effective
Figure 3. MD between the core laboratory FTV and Aegis FTV for
each visit at each site. Sites 2, 5, and 8 did not have enough analyz-
able cases for meaningful statistical analysis. MD, mean value of the
magnitude of the difference between the two FTV measures.
Translational Oncology Vol. 7, No. 1, 2014 MRI Breast Tumor Volume Validation Newitt et al. 99
difference between the predictive models of FTVs fromHologic’s Aegis
platform relative to the UCSF core laboratory’s platform; the hazard
ratio per unit increase in the final, presurgery FTV was identical for
both platforms at 1.043 (95% CI = 1.023-1.064; P < .0001).
The multiple potential error sources described above illustrate the
importance of attention to implementation details when porting
quantitative image analysis algorithms between platforms. This is
of particular concern when they are intended for use in multisite
studies with the possibility of significant variability in image acquisi-
tion protocol compliance and image quality. Nonetheless, the high
correlations and similar results from the survival analyses illustrate
the robustness of MRI volume measures for prediction of response
in the breast cancer neoadjuvant treatment regimen.
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